Extended myositis-specific and -associated ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Extended myositis-specific and -associated antibodies profile in systemic sclerosis: a cross-sectional study
Author(s) :
Leurs, Amelie [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE (Ex-Liric)]
Dubucquoi, Sylvain [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Machuron, Francois [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Balden, Maité [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Renaud, Florence [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277
Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290
Rogeau, Stephanie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Lopez, Benjamin [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Lambert, Marc [Auteur]
Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement (RID-AGE) - U1167
Morell-Dubois, Sandrine [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Maillard, Hélène [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Behal, Helene [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Hachulla, Eric [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Launay, David [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Sobanski, Vincent [Auteur]
Lille Inflammation Research International Center (LIRIC) - U995
Institute for Translational Research in Inflammation - U 1286 [INFINITE (Ex-Liric)]
Institute for Translational Research in Inflammation - U 1286 [INFINITE (Ex-Liric)]
Dubucquoi, Sylvain [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Machuron, Francois [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Balden, Maité [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Renaud, Florence [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277
Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290
Rogeau, Stephanie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Lopez, Benjamin [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Lambert, Marc [Auteur]
Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement (RID-AGE) - U1167
Morell-Dubois, Sandrine [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Maillard, Hélène [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Behal, Helene [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Hachulla, Eric [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Launay, David [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Sobanski, Vincent [Auteur]
Lille Inflammation Research International Center (LIRIC) - U995
Institute for Translational Research in Inflammation - U 1286 [INFINITE (Ex-Liric)]
Journal title :
Joint Bone Spine
Abbreviated title :
Joint Bone Spine
Volume number :
88
Pages :
105048
Publisher :
Elsevier
Publication date :
2020-07-09
ISSN :
1778-7254
Keyword(s) :
Myositis-associated antibodies
Immunoblot assays
Systemic sclerosis
Myositis-specific antibodies
Immunoblot assays
Systemic sclerosis
Myositis-specific antibodies
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
In systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM), auto-antibodies are used in daily practice as potent biomarkers of clinical phenotypes. This study aimed at estimating the prevalence of myositis-specific ...
Show more >In systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM), auto-antibodies are used in daily practice as potent biomarkers of clinical phenotypes. This study aimed at estimating the prevalence of myositis-specific (MSA) and myositis-associated (MAA) auto-antibodies in a well-characterised SSc patients cohort using two different immunoblot assays, and studying their clinical associations. In this cross-sectional study, the sera of 300 consecutive patients were tested at the same time with myositis antibodies Euroimmun® and D-tek® immunoblot assays. Prevalence of MSA/MAA, MSA and MAA were 17.0%, 8.0% and 9.7%, respectively. When combining results of both tests, anti-PM/Scl 100 were found in 5.0% (95% confidence interval 2.8; 8.1); anti-PM/Scl 75 and anti-TIF1γ in 3.7% (1.8; 6.5); anti-Ku 3.0% (1.4; 5.6); anti-MDA5 in 1.3% (0.4; 3.4); anti-Mi-2 β, anti-NXP2, anti-PL-7 and anti-SRP in 0.7% (0.08; 2.4); anti-EJ and anti-PL-12 in 0.3% (0.01; 1.8) of patients. No reactivity against SAE1, Jo-1 or OJ was observed. Anti-PM/Scl 75 antibodies were associated with interstitial lung disease (80% vs. 42%) and myositis (27% vs. 3%); anti-Ku antibodies were associated with myositis (33% vs. 3%). In this cross-sectional study of 300 SSc patients, the prevalence of MSA/MAA, MSA and MAA using immunoblot assays were 17.0%, 8.0% and 9.7%, respectively. MAA positivity was associated with ILD and myositis, but this study did not highlight any clinical associations with MSA positivity.Show less >
Show more >In systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM), auto-antibodies are used in daily practice as potent biomarkers of clinical phenotypes. This study aimed at estimating the prevalence of myositis-specific (MSA) and myositis-associated (MAA) auto-antibodies in a well-characterised SSc patients cohort using two different immunoblot assays, and studying their clinical associations. In this cross-sectional study, the sera of 300 consecutive patients were tested at the same time with myositis antibodies Euroimmun® and D-tek® immunoblot assays. Prevalence of MSA/MAA, MSA and MAA were 17.0%, 8.0% and 9.7%, respectively. When combining results of both tests, anti-PM/Scl 100 were found in 5.0% (95% confidence interval 2.8; 8.1); anti-PM/Scl 75 and anti-TIF1γ in 3.7% (1.8; 6.5); anti-Ku 3.0% (1.4; 5.6); anti-MDA5 in 1.3% (0.4; 3.4); anti-Mi-2 β, anti-NXP2, anti-PL-7 and anti-SRP in 0.7% (0.08; 2.4); anti-EJ and anti-PL-12 in 0.3% (0.01; 1.8) of patients. No reactivity against SAE1, Jo-1 or OJ was observed. Anti-PM/Scl 75 antibodies were associated with interstitial lung disease (80% vs. 42%) and myositis (27% vs. 3%); anti-Ku antibodies were associated with myositis (33% vs. 3%). In this cross-sectional study of 300 SSc patients, the prevalence of MSA/MAA, MSA and MAA using immunoblot assays were 17.0%, 8.0% and 9.7%, respectively. MAA positivity was associated with ILD and myositis, but this study did not highlight any clinical associations with MSA positivity.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
CNRS
Inserm
Institut Pasteur de Lille
Université de Lille
CNRS
Inserm
Institut Pasteur de Lille
Université de Lille
Collections :
- Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement (RID-AGE) - U1167
- Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
- METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
- Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290
Submission date :
2021-07-06T12:49:34Z
2024-03-20T10:18:14Z
2024-03-20T10:18:14Z